Key facts today
JPMorgan has initiated coverage of OPKO Health with a 'Neutral' rating, while analysts have an average rating of 'buy' for the company, with a mean price target set at $3.99.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.3 ILS
−193.93 M ILS
2.60 B ILS
303.34 M
About Opko Health, Inc.
Sector
Industry
CEO
Phillip Frost
Website
Headquarters
Miami
Founded
1991
FIGI
BBG005579TC1
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
OPK - potential biotech gap playOPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation
OPK CatalystFDA approval on Jan 31st so this does have a time frame in which you can pull profits. They are partnered with pfizer on a drug that helps with HGH deficiency in human trials. Currently super low valuation and the fact that this drug will be in the public eye could make this pop. My expectations wil
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
OPK5991654
OPKO Health, Inc. 3.75% 15-JAN-2029Yield to maturity
−6.09%
Maturity date
Jan 15, 2029
OPK4048118
OPKO Health, Inc. 3.0% 01-FEB-2033Yield to maturity
—
Maturity date
Feb 1, 2033
OPK5733212
OPKO Health, Inc. 3.75% 15-JAN-2029Yield to maturity
—
Maturity date
Jan 15, 2029
OPK4020628
OPKO Health, Inc. 3.0% 01-FEB-2033Yield to maturity
—
Maturity date
Feb 1, 2033
See all OPK bonds
Related stocks
Frequently Asked Questions
The current price of OPK is 530.8 ILA — it has decreased by −5.80% in the past 24 hours. Watch OPKO HEALTH stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange OPKO HEALTH stocks are traded under the ticker OPK.
OPK stock has risen by 1.67% compared to the previous week, the month change is a −20.75% fall, over the last year OPKO HEALTH has showed a 12.67% increase.
We've gathered analysts' opinions on OPKO HEALTH future price: according to them, OPK price has a max estimate of 3,070.03 ILA and a min estimate of 722.36 ILA. Watch OPK chart and read a more detailed OPKO HEALTH stock forecast: see what analysts think of OPKO HEALTH and suggest that you do with its stocks.
OPK stock is 7.50% volatile and has beta coefficient of 0.19. Track OPKO HEALTH stock price on the chart and check out the list of the most volatile stocks — is OPKO HEALTH there?
Today OPKO HEALTH has the market capitalization of 3.56 B, it has increased by 0.066% over the last week.
Yes, you can track OPKO HEALTH financials in yearly and quarterly reports right on TradingView.
OPKO HEALTH is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
OPK earnings for the last quarter are 0.036 ILA per share, whereas the estimation was −0.34 ILA resulting in a 110.71% surprise. The estimated earnings for the next quarter are −0.26 ILA per share. See more details about OPKO HEALTH earnings.
OPKO HEALTH revenue for the last quarter amounts to 668.97 M ILA, despite the estimated figure of 566.28 M ILA. In the next quarter, revenue is expected to reach 612.10 M ILA.
OPK net income for the last quarter is 51.01 M ILS, while the quarter before that showed 92.88 M ILS of net income which accounts for −45.08% change. Track more OPKO HEALTH financial stats to get the full picture.
No, OPK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 25, 2025, the company has 3 K employees. See our rating of the largest employees — is OPKO HEALTH on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OPKO HEALTH EBITDA is −638.89 M ILS, and current EBITDA margin is −24.59%. See more stats in OPKO HEALTH financial statements.
Like other stocks, OPK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OPKO HEALTH stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So OPKO HEALTH technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating OPKO HEALTH stock shows the sell signal. See more of OPKO HEALTH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.